Article

Cost-effectiveness of the next generation of RSV intervention strategies

2019-10-22

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> With a suite of promising new RSV prophylactics on the horizon, including long-acting monoclonal antibodies and new vaccines, it is likely that one or more of these will replace the current monoclonal Palivizumab programme. However, choosing the optimal intervention programme will require balancing the costs of the programmes with the health benefits accrued. <h4>Methods</h4>...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8f8af370-5662-5bff-a96c-36653035cc25
DOI: 10.1101/19009977

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of the next generation of RSV intervention strategiesDOI 10.1101/19009977Read

Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South AfricaSemantic proximity Read

Cost-effectiveness of respiratory syncytial virus vaccination for older adults: a modelling analysisSemantic proximity Read

Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa DataSemantic proximity Read

The burden of RSV-associated illness in children aged <5 years, South Africa, 2011 to 2016Semantic proximity Read

Beyond Efficacy: Policy, Delivery, and Equity Determinants of Long-Acting Monoclonal Antibody Uptake for Infant RSV Prevention—A WAidid Consensus DocumentSemantic proximity Read

Clinical and economic burden of Respiratory Syncytial Virus in children aged 0-5 years in ItalySemantic proximity Read

RSV--a substantial slice of the airway disease burden and the way to a vaccine.Semantic proximity Read

Study protocol: Effectiveness of the maternal RSVpreF vaccine by virus typeSemantic proximity Read

Optimising age coverage of seasonal influenza vaccination in England: A mathematical and health economic evaluationSemantic proximity Read

The long road to protect infants against severe RSV lower respiratory tract illnessSemantic proximity Read

Economic Burden of RSV-Associated Hospitalizations in Switzerland: A Nationwide Analysis (2017–2023)Semantic proximity Read

Estimation of GP visits, hospitalizations and deaths attributable to RSV and influenza and costs associated with hospitalizations in older adults in France, 2010-2020Semantic proximity Read